10039-64-2

Basic information

• Product Name: ethyl 3-(m-aminophenyl)propionate
• Synonyms: ethyl 3-(m-aminophenyl)propionate;3-(3-Aminophenyl)propanoic acid ethyl ester;3-Aminobenzenepropionic acid ethyl ester;Einecs 233-119-3;ETHYL 3-(3-AMINOPHENYL)PROPANOATE HCL;ETHYL 3-(3-AMINOPHENYL)PROPIONATE
• CAS NO: 10039-64-2
• Molecular Formula: C₁₁H₁₅NO₂
• Molecular Weight: 193.2423
• EINECS: 233-119-3
• Mol File: 10039-64-2.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 313.7°C at 760 mmHg
• Flash Point: 166.6°C
• Appearance: /
• Density: 1.088g/cm³
• Vapor Pressure: 0.000488mmHg at 25°C
• Refractive Index: 1.54
• PKA: 4.54±0.10(Predicted)
• CAS DataBase Reference: ethyl 3-(m-aminophenyl)propionate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(m-aminophenyl)propionate(10039-64-2)
• EPA Substance Registry System: ethyl 3-(m-aminophenyl)propionate(10039-64-2)

Safety Data

• Hazardous Substances Data: 10039-64-2(Hazardous Substances Data)

Usage

General Description

Ethyl 3-(m-aminophenyl)propionate is a chemical compound often used in organic synthesis. Its chemical formula is C11H13NO2, and it is categorized under aromatic propionic acid. It has a molar mass of 191.22 g/mol. This chemical typically appears as a crystalline solid. It may present risks if ingested, inhaled, or contacted with skin and eyes due to its potentially irritating or harmful nature. Therefore, proper handling and safety precautions are necessary when dealing with this compound. Its applications can vary vastly across different industries due to its property as a reactive organic compound; however, specific details often depend on the context of its use.

InChI:InChI=1/C11H15NO2/c1-2-14-11(13)7-6-9-4-3-5-10(12)8-9/h3-5,8H,2,6-7,12H2,1H3

Upstream product

• 621-19-2 (E)-ethyl 3-(3-nitrophenyl)acrylate 
• 7440-44-0 pyrographite 
• 7116-33-8 ethyl 3-(3-nitrophenyl)propanoate 
• 1664-57-9 3-(3-nitrophenyl)propanoic acid 
• 64-17-5 ethanol 
• 1664-54-6 3-(3-aminophenyl)propionic acid 
• 99-61-6 3-nitro-benzaldehyde 
• 555-68-0 m-Nitrocinnamic Acid 
• 5396-71-4 ethyl 3-(3-nitrophenyl)acrylate 

Downstream Products

• 1308256-05-4 ethyl 3-(2-(chlorosulfonyl)-5-(2,2,2-trifluoroacetamido)phenyl)propanoate 
• 1308254-79-6 ethyl 3-(2-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)-5-(2,2,2-trifluoroacetamido)phenyl)propanoate 
• 1308255-01-7 methyl 3-(5-amino-2-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)phenyl)propanoate 
• 1308255-02-8 ethyl 3-(5-amino-2-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)phenyl)propanoate 
• 1261078-81-2 3-(3-(quinoxalin-3-ylamino)phenyl)propanoic acid 
• 1261078-78-7 3-(3-(6-nitroquinoxalin-3-ylamino)phenyl)propanoic acid 
• 1310877-60-1 ethyl 3-(3-(6-nitroquinoxalin-3-ylamino)phenyl)propanoate 
• 4252-25-9 3-(3-(bis(2-chloroethyl)amino)phenyl)propanoic acid 

Relevant articles and documents

Short synthesis of ethyl 3-(3-aminophenyl)propanoate

A short and effective synthesis of ethyl 3-(3-aminophenyl)propanoate is presented, employing a tandem Knoevenagel condensation/alkylidene reduction of 3-nitrobenzaldehyde with Meldrum's acid in TEAF (triethylammonium formate) followed by reduction of the

Development of second-generation small-molecule RhoA inhibitors with enhanced water solubility, tissue potency, and significant in vivo efficacy

RhoA, a member of the Rho GTPases, is involved in a variety of cellular functions and could be a suitable therapeutic target for the treatment of cardiovascular diseases. However, few small-molecule RhoA inhibitors have been reported. Based on our previously reported lead compounds, 32 new 2-substituted quinoline (or quinoxaline) derivatives were synthesized and tested in biological assays. Six compounds showed high RhoA inhibitory activities, with IC50 values of 1.17-1.84 μM. Among these, (E)-3-(3-(ethyl(quinolin-2-yl)amino)phenyl)acrylic acid (26b) and (E)-3-(3-(butyl(quinolin-2-yl)amino)phenyl)acrylic acid (26d) demonstrated noticeable vasorelaxation effects against phenylephrine-induced contraction in thoracic aorta artery rings, and compound 26b had good water solubility and showed significant in vivo efficacy, which was similar to that of 5-(1,4-diazepane-1-sulfonyl)isoquinoline (fasudil) in a subarachnoid hemorrhage-cardiovascular model. To the best of our knowledge, compound 26b is the first example of a small-molecule RhoA inhibitor with potent in vivo efficacy, which could serve as a good lead for designing cardiovascular agents.

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

PROTEASOME ACTIVITY ENHANCING COMPOUNDS

The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, the methods of synthesis of the compouds of interest, and to methods for the treatment of a condition associated with a dysfunction in proteostasis, such as cancer, inflammatory conditions, neurodegeneration, metabolic conditions, comprising administering an effective amount of a compound of the invention.